


Description

| | |
|-------------------|--|
| Product Name | PHA-665752 |
| Brief Description | Inhibitors |
| Purification | 99.35% |
| Target Name | Bcr-Abl inhibitor; c-Met/HGFR inhibitor; FGFR inhibitor; VEGFR inhibitor |
| Calculated MW | 641.61 |
| Formulation | C32H34Cl2N4O4S |
| Storage | 3 years -20°C powder; 2 years -80°C in solvent; |

Images



Product Description

Research

Area: Cancer SMILES: CC1=C(C(=O)N2CCC[C@@H]2CN2CCCC2)C(C)=C(N1)C=C1/C(=O)NC2=C1C=C(C=C2)S(=O)(=O)CC1=C(Cl)C=CC=C1Cl
 |r,c:1,19,28,31,33,40,43,45|Pathways: Angiogenesis; Tyrosine Kinase/Adaptors; Cytoskeletal Signaling Receptor: c-Abl; c-Met; RON; FGFR1;
 Flk1 Boling pt: Melting pt: Solubility: DMSO: 128 mg/mL (199.49 mM) Ethanol:

References

1. Christensen JG, et al. Cancer Res, 2003, 63(21), 7345-7355.

Note: This product is for in vitro research use only